Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Starpharma Holdings (ASX:SPL) is well-positioned for business growth, we believe.

Reading Time: < 1 minute

Starpharma Holdings (ASX:SPL) has been making headlines recently, with investors wondering about its cash burn and the potential impact on shareholders. Despite the company’s history of losses, there may be hope for those who have invested in this biotech company at the right price.

In December 2023, Starpharma Holdings had AU$32m in cash and no debt. With a cash burn rate of AU$6.5m per year, the company had a cash runway of about 4.9 years. This gives Starpharma Holdings the time it needs to develop its business and potentially find success with new treatments.

While the company has been reducing its cash burn and showing impressive revenue growth of 131%, there are still risks to consider. If Starpharma Holdings needs to raise more cash for faster growth, shareholders could face dilution. However, with a cash burn of only 14% of its market capitalization, the company may not have much trouble raising additional funds.

Overall, despite some concerns about its cash burn situation, Starpharma Holdings seems to be on a positive path. Investors should keep an eye on the company’s progress and consider the potential risks before making any investment decisions. With careful analysis and a long-term perspective, shareholders may still have a chance to profit from this promising biotech company.

Taylor Swifts New Album Release Health issues from using ACs Boston Marathon 2024 15 Practical Ways To Save Money